INGENIA has two lead product candidates in its pipeline:
∙IGT-427 is a bi-specific antibody with a site-specific bioconjugate for an extended ocular half-life. It is an early-stage asset, targeting primarily the DME market. We are generating a pre-clinical package to support its transition to IND in the next 24 months. IGT-427 can be first-line therapy for DME patients if it demonstrates comparable or superior efficacy and dosing advantage to SoC. Pharma companies that are marketing current drugs in the ophthalmic space and/or new pharma companies with new additional portfolios could become our development and commercial partner. Building on this successful program, the partnership could expand the indication space of IGT-427 into additional ophthalmic diseases like wAMD, RVO, and mCNV.
∙IGT-302 is a humanized monoclonal antibody with a site-specific bioconjugate for an extended ocular half-life. It is targeting primarily glaucoma. We are generating a pre-clinical package to support its transition to IND in the next 24 months. IGT-302 can be a first-line therapy if it demonstrates comparable efficacy and dosing advantage to SoC. Pharma companies that are marketing current drugs in the ophthalmic space and/or new pharma companies with new additional portfolios could become our development and commercial partner.